Comparison of SF-36 scores of participants with residual limb pain with a VAS score ≥5 and participants with a VAS score <5. by Martin C. Berli (9427264)

pDNA-PK levels are decreased in absence of cGAS. by Elona Gusho (4688170)

Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric <i>in silico</i> ROCOCO trial by Daniëlle B. P. Eekers (5560430)

The RMSF plot of each mutation was aligned to the RMSF plot of the native PC, where black, blue, orange, red, green, and purple line describes native, L305R, W342C, G403R, V420E, a... by Mahvash Farajzadeh-Dehkordi (17468232)

Fig 5 - by Debarpan Dhar (724473)

DART-ID decreases missing datapoints across runs. by Albert Tian Chen (6900215)

“…Only peptides seen in >50% of experiments are included. (<b>b</b>) Decrease in missing data across all runs after applying DART-ID, for SCoPE-MS and the two bulk sets from <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007082#pcbi.1007082.g004" target="_blank">Fig 4</a> at 1% FDR. …”

mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”

<i>k_i</i> impacts on<i>V</i>^<i>C</i>(<i>W</i>). by Yan Zhao (58882)

<i>μ_G</i> impacts on <i>V</i>^<i>C</i>(<i>W</i>). by Yan Zhao (58882)

Trial profile. by Chanel Avenant (409756)

“…Both contraceptives substantially decreased, from D0 to 25W, the total testosterone [DMPA-IM D0 0.560, 25W 0.423 nmol/L, -24.3% (p < 0.0001); NET-EN D0 0.551, 25W 0.253 nmol/L, -54.1%, (p < 0.0001)], SHBG [DMPA-IM D0 45.0, 25W 32.7 nmol/L, -29.8% (p < 0.0001); NET-EN D0 50.2, 25W 17.6 nmol/L, -65.1% (p < 0.0001)], and calculated free testosterone levels [DMPA-IM D0 6.87, 25W 5.38 pmol/L, -17.2% (p = 0.0371); NET-EN D0 6.00, 25W 3.70, -40.0% (p < 0.0001)]. …”

The minimum inhibitory concentrations (µg/mL) and the minimum bactericidal concentrations (µg/mL) of synthesized 1,2,3,5-tetrazine derivatives. by Jean Paul Dzoyem (6424445)

Subjects:

Ivermectin significantly decreases <i>L</i>. <i>loa</i> mf in BALB/c mice. by Rene Bilingwe Ayiseh (6900296)

cGAS inhibition decreases ISG RNA in H358 cells. by Lorellin A. Durnell-Bettis (22656332)

BAL total lipid and lipid classes decreased in COPD correlating with FEV1. by Christina W. Agudelo (8415171)

Firing rates of PNs (as maximum activity) in response to a single synchronous triangular pulse of 50 ms duration applied to both ORN groups. by Mario Pannunzi (553941)

Firing rates of ORNs (as maximum activity) in response to a single synchronous triangular pulse of 50 ms duration applied to both ORN groups. by Mario Pannunzi (553941)

Example of coloration measurement taken in ImageJ for <i>M</i>. <i>mercenaria</i> specimen w48 at the conclusion of the 20.5-week experiment. by Teagan McMahon (20108036)

Subjects:

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Dilution coefficient (τ) at 25°C and 37°C for 5 suspending media compared to that of a physiological value of τ = 1. by Chadapust J. Sudsiri (14670602)

S5 Fig - by Meihui Chen (1670020)